Eric S. Bachman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eric S. Bachman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Alessandra DiBacco
Departments of Oncology-Pharmacology, Lab Animal Research and Pharmacology Merck Research Laboratories, Boston, Massachusetts, United States of America
1 shared publicationAnjili Mathur
Departments of Oncology-Pharmacology, Lab Animal Research and Pharmacology Merck Research Laboratories, Boston, Massachusetts, United States of America
1 shared publicationAnqi Zhang
Department of Medicine (E.C., T.T., S.Ba., S.Bh., M.L., J.U., A.Z.), Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, Massachusetts 02118
1 shared publicationDiana Gargano
Departments of Oncology-Pharmacology, Lab Animal Research and Pharmacology Merck Research Laboratories, Boston, Massachusetts, United States of America
1 shared publicationGordana Olbina
Intrinsic LifeSciences LLC (M.W., G.O., V.O.), La Jolla, California 92037
1 shared publicationJagadish Ulloor
Department of Medicine (E.C., T.T., S.Ba., S.Bh., M.L., J.U., A.Z.), Section of Endocrinology, Diabetes and Nutrition, Boston University School of Medicine, Boston, Massachusetts 02118
1 shared publication
Latest Publications
- Open Access
- 28 October 2010
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (18) , 1769-1770
A School-Based Intervention for Diabetes Risk Reduction
The HEALTHY Study Group (July 29 issue)1 found that a school-based intervention did not result in greater decreases in overweight and obesity than those seen in control schools but did result in significantly greater reductions in some indexes of adiposity. Recent views seem to overlook the role of increasing energy expenditure to prevent obesity. Purportedly definitive statements such as “. . . at best, behavioral and nutrition interventions in schools or within the home have limited success in preventing weight gain in children”2 and “. . . cigarette smoking remains by far the most common cause of preventable death and disability in the United States”3 are premature and incorrect, respectively. Objective measures of physical activity (accelerometry) in children show a strong, inverse relationship between physical activity and obesity.4 Posturing and fidgeting (non–exercise-associated thermogenesis) may explain wide differences in weight gain among people who have been overfed.5 The rate of another source of energy expenditure — walking to school — has in fact decreased since the 1960s, from 50% to less than 10%.6 Must we wait for formal evidence from a clinical trial before enacting changes such as designing thoroughfares to better accommodate pedestrians and bicyclists and reduce the use of automobiles, enforcing traffic laws strictly, encouraging walking to school, and mandating compulsory physical education? If we could go back in time and strap an accelerometer to a child living in the 1960s, how would the data compare with those from a child today?
- 28 October 2010
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (18) , 1769-1770
Open AccessA School-Based Intervention for Diabetes Risk Reduction
The HEALTHY Study Group (July 29 issue)1 found that a school-based intervention did not result in greater decreases in overweight and obesity than those seen in control schools but did result in significantly greater reductions in some indexes of adiposity. Recent views seem to overlook the role of increasing energy expenditure to prevent obesity. Purportedly definitive statements such as “. . . at best, behavioral and nutrition interventions in schools or within the home have limited success in preventing weight gain in children”2 and “. . . cigarette smoking remains by far the most common cause of preventable death and disability in the United States”3 are premature and incorrect, respectively. Objective measures of physical activity (accelerometry) in children show a strong, inverse relationship between physical activity and obesity.4 Posturing and fidgeting (non–exercise-associated thermogenesis) may explain wide differences in weight gain among people who have been overfed.5 The rate of another source of energy expenditure — walking to school — has in fact decreased since the 1960s, from 50% to less than 10%.6 Must we wait for formal evidence from a clinical trial before enacting changes such as designing thoroughfares to better accommodate pedestrians and bicyclists and reduce the use of automobiles, enforcing traffic laws strictly, encouraging walking to school, and mandating compulsory physical education? If we could go back in time and strap an accelerometer to a child living in the 1960s, how would the data compare with those from a child today?
- Open Access
- 1 October 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (10) , 4743-4747
Testosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis
Context: The mechanisms by which testosterone increases hemoglobin and hematocrit are unknown. Objective: The aim was to test the hypothesis that testosterone-induced increase in hematocrit is associated with suppression of the iron regulatory peptide hepcidin. Participants: Healthy younger men (ages 19–35 yr; n = 53) and older men (ages 59–75 yr; n = 56) were studied. Methods: Weekly doses of testosterone enanthate (25, 50, 125, 300, and 600 mg) were administered over 20 wk, whereas endogenous testosterone was suppressed by monthly GnRH agonist administration. Blood and serum parameters from each individual were measured at wk 0, 1, 2, 4, 8, and 20. Longitudinal analyses were performed to examine the relationship between hepcidin, hemoglobin, hematocrit, and testosterone while controlling for potential confounders. Results: High levels of testosterone markedly suppressed serum hepcidin within 1 wk. Hepcidin suppression in response to testosterone administration was dose-dependent in older men and more pronounced than in young men, and this corresponded to a greater rise in hemoglobin in older men. Serum hepcidin levels at 4 and 8 wk were predictive of change in hematocrit from baseline to peak levels. Conclusion: Testosterone administration is associated with suppression of serum hepcidin. Greater increases in hematocrit in older men during testosterone therapy are related to greater suppression of hepcidin.
- 1 October 2010
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 95 (10) , 4743-4747
Open AccessTestosterone Suppresses Hepcidin in Men: A Potential Mechanism for Testosterone-Induced Erythrocytosis
Context: The mechanisms by which testosterone increases hemoglobin and hematocrit are unknown. Objective: The aim was to test the hypothesis that testosterone-induced increase in hematocrit is associated with suppression of the iron regulatory peptide hepcidin. Participants: Healthy younger men (ages 19–35 yr; n = 53) and older men (ages 59–75 yr; n = 56) were studied. Methods: Weekly doses of testosterone enanthate (25, 50, 125, 300, and 600 mg) were administered over 20 wk, whereas endogenous testosterone was suppressed by monthly GnRH agonist administration. Blood and serum parameters from each individual were measured at wk 0, 1, 2, 4, 8, and 20. Longitudinal analyses were performed to examine the relationship between hepcidin, hemoglobin, hematocrit, and testosterone while controlling for potential confounders. Results: High levels of testosterone markedly suppressed serum hepcidin within 1 wk. Hepcidin suppression in response to testosterone administration was dose-dependent in older men and more pronounced than in young men, and this corresponded to a greater rise in hemoglobin in older men. Serum hepcidin levels at 4 and 8 wk were predictive of change in hematocrit from baseline to peak levels. Conclusion: Testosterone administration is associated with suppression of serum hepcidin. Greater increases in hematocrit in older men during testosterone therapy are related to greater suppression of hepcidin.
- Open Access
- 30 September 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (9) , e7286
Splenectomy Normalizes Hematocrit in Murine Polycythemia Vera
Splenic enlargement (splenomegaly) develops in numerous disease states, although a specific pathogenic role for the spleen has rarely been described. In polycythemia vera (PV), an activating mutation in Janus kinase 2 (JAK2V617) induces splenomegaly and an increase in hematocrit. Splenectomy is sparingly performed in patients with PV, however, due to surgical complications. Thus, the role of the spleen in the pathogenesis of human PV remains unknown. We specifically tested the role of the spleen in the pathogenesis of PV by performing either sham (SH) or splenectomy (SPL) surgeries in a murine model of JAK2V617F-driven PV. Compared to SH-operated mice, which rapidly develop high hematocrits after JAK2V617F transplantation, SPL mice completely fail to develop this phenotype. Disease burden (JAK2V617) is equivalent in the bone marrow of SH and SPL mice, however, and both groups develop fibrosis and osteosclerosis. If SPL is performed after PV is established, hematocrit rapidly declines to normal even though myelofibrosis and osteosclerosis again develop independently in the bone marrow. In contrast, SPL only blunts hematocrit elevation in secondary, erythropoietin-induced polycythemia. We conclude that the spleen is required for an elevated hematocrit in murine, JAK2V617F-driven PV, and propose that this phenotype of PV may require a specific interaction between mutant cells and the spleen.
- 30 September 2009
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (9) , e7286
Open AccessSplenectomy Normalizes Hematocrit in Murine Polycythemia Vera
Splenic enlargement (splenomegaly) develops in numerous disease states, although a specific pathogenic role for the spleen has rarely been described. In polycythemia vera (PV), an activating mutation in Janus kinase 2 (JAK2V617) induces splenomegaly and an increase in hematocrit. Splenectomy is sparingly performed in patients with PV, however, due to surgical complications. Thus, the role of the spleen in the pathogenesis of human PV remains unknown. We specifically tested the role of the spleen in the pathogenesis of PV by performing either sham (SH) or splenectomy (SPL) surgeries in a murine model of JAK2V617F-driven PV. Compared to SH-operated mice, which rapidly develop high hematocrits after JAK2V617F transplantation, SPL mice completely fail to develop this phenotype. Disease burden (JAK2V617) is equivalent in the bone marrow of SH and SPL mice, however, and both groups develop fibrosis and osteosclerosis. If SPL is performed after PV is established, hematocrit rapidly declines to normal even though myelofibrosis and osteosclerosis again develop independently in the bone marrow. In contrast, SPL only blunts hematocrit elevation in secondary, erythropoietin-induced polycythemia. We conclude that the spleen is required for an elevated hematocrit in murine, JAK2V617F-driven PV, and propose that this phenotype of PV may require a specific interaction between mutant cells and the spleen.